[Acute leukemia and various hematosarcomas. Trial treatment with a second derivative of podophyllotoxin (4-demethyl-epipodophyllotoxin beta D ethylidene glucoside VP 16213 or EPE)].
D000293:Adolescent; D000328:Adult; D000368:Aged; D000380:Agranulocytosis / Q000139:chemically induced; D000505:Alopecia / Q000139:chemically induced; D002648:Child; D002675:Child, Preschool; D005260:Female; D006689:Hodgkin Disease / Q000188:drug therapy; D006801:Humans; D007223:Infant; D007938:Leukemia / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000188:drug therapy; D007948:Leukemia, Monocytic, Acute / Q000188:drug therapy; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy; D008206:Lymphatic Diseases / Q000188:drug therapy*; D008223:Lymphoma / Q000188:drug therapy*; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011034:Podophyllotoxin / Q000009:adverse effects / Q000627:therapeutic use*; D013921:Thrombocytopenia / Q000139:chemically induced
D011034:Podophyllotoxin
Leucémies aiguës et hématosarcomes divers. Essai de traitement par un second dérive de la podophyllotoxine (le 4-déméthyl-épipodophyllotoxine bêta. D. éthylidène glucoside VP 16213 ou EPE.